CEO Angelos Stergiou confirmed Sellas Life Sciences is nearing the 80th event in its Phase 3 Regal trial. This milestone triggers the final data analysis for the company’s acute myeloid leukemia (AML) treatment.
The company entered a quiet period regarding clinical updates to prepare for database lock and regulatory filings.
Retail investors interpreted the operational update as a signal for a potential merger or acquisition. The company’s market capitalization increased significantly in 2026 ahead of the pivotal data release.